Navigation Links
Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
Date:10/25/2010

ity was similar in all vaccine groups. Functional opsonozation-uptake could be shown and correlated well with vaccine-induced IgG titers. Induction of functional antibodies is expected to be the major protective mechanism against Pseudomonas aeruginosa infections. Immune responses in intensive care patients appeared weaker compared to results from a preceding Phase I trial in healthy volunteers. This was not unexpected due to the reduced general health condition of patients enrolled.

Although this trial was not powered for efficacy the Clinical Endpoint Committee (CEC) confirmed infection rates and mortality were recorded within the secondary endpoints analysis.

A lower mortality rate was observed in all vaccine groups as compared to the control group.  The reduction in mortality rate was statistically significant (p = 0.0196) for the non-adjuvanted vaccine (21.7% day 28 mortality in the not-adjuvanted IC43 group compared to 40.0% day 28 mortality in the placebo group).

No significant difference in Pseudomonas aeruginosa infection rates between any of the groups was apparent. However, this is likely to be due to the relatively small sample size of the current Phase II study. Larger, sufficiently powered clinical studies would be required to validate and verify any vaccine effects on mortality and infection rates.

As another key objective, the current Phase II trial investigated the feasibility of performing pivotal efficacy studies in this difficult target population: Final data confirm the anticipated number of Pseudomonas aeruginosa infections. The observed attack rate of 6 - 14% is well within expectations as only study sites with estimated Pseudomonas aeruginosa invasive infection rates of 10 - 25% were selected for this trial. These results confirm the development strategy for Intercells's Pseudomonas aeruginosa vaccine and could allow a pivotal assessment o
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
2. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
3. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
4. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
5. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
6. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
7. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
8. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
9. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
10. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
11. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... YORK, July 4, 2011 ... market research report is available ... Global Pharmaceutical Industry Outlook ... Trends and Opportunities, Buyer Spend ...
... 2011 Simulated Environment Concepts (SMEV.PK), the manufacturer ... equipment, announced today that the Company has entered into what ... Management expects that much of the difficult items ... believes it is much more knowledgeable today about the auditing ...
Cached Medicine Technology:Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 2Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 3Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 4Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 5Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 6Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 7Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 8Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 9Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 10Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 11Simulated Environment Concepts Nears Audit Completion 2Simulated Environment Concepts Nears Audit Completion 3
(Date:4/14/2014)... Significant advances have been made in chemotherapy over the ... avoiding healthy tissues continues to be a major challenge. ... drug delivery, including the use of nanocarriers, or capsules, ... locations in the body. , The catch? These carriers ...
(Date:4/14/2014)... at Henry Ford Hospital reached a medical milestone April ... a novel way to access the heart. , Henry ... performing the unique procedure called transcaval valve replacement, which ... , Northern Michigan resident Viola Waller, 80, underwent Henry ...
(Date:4/14/2014)... , , Penicillin, one of the scientific marvels of the ... it once won against bacterial infections. But scientists at ... new approach to restoring its combat effectiveness, even against ... the power of the penicillin family of drugs since ...
(Date:4/14/2014)... their radiation treatment decisions leaves cancer patients feeling more ... distress around the experience, researchers from the Perelman ... report in the journal Cancer . , In ... Neha Vapiwala, MD , an associate professor in the ...
(Date:4/14/2014)... 2014 Popular web information on colorectal cancer is ... doesn,t address the appropriate risks to and concerns of ... suggests. , In a review of a dozen popular ... colorectal cancer screening were written beyond the recommended sixth-grade ...
Breaking Medicine News(10 mins):Health News:Nano shake-up 2Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3
... THURSDAY, Nov. 5 (HealthDay News) -- A program called ... says a U.S. government report. , Over three years, ... percent decrease in the number of students involved in ... report. The number of students who reported experiencing or ...
... adults, producing mild-to-moderate illness , THURSDAY, Nov. 5 (HealthDay ... the predominant flu strain worldwide, although it shows no ... mild-to-moderate symptoms in most people, the World Health Organization,s ... swine flu accounts for up to 70 percent of ...
... ... , ... Now there are some five-star reasons for Houston-area Medicare beneficiaries to choose KelseyCare ... its annual Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey, and KelseyCare Advantage ...
... 5 Attorneys from Dallas, Rasansky Law Firm ... on behalf of the mother of a 2-year-old girl who choked ... ago. The lawsuit includes claims that the day care,s owners quickly ... child,s death from showing up on a state licensing database. , ...
... , FAIRFIELD, Calif., Nov. 5 ChemSW is pleased ... The only Internet site that offers quick, confidential ... listed ChemSW as the top rated vendor overall in ... Despite an overall gloomy report where the customer satisfaction ...
... Nov. 5 Quantros, Inc., an industry leader in ... of care data surveillance solutions, today announced the acquisition ... a publicly traded company spun off from Cardinal Health ... not disclosed. , This latest addition to the ...
Cached Medicine News:Health News:School Violence Drops With Federal Program 2Health News:Swine Flu Virus Dominant Strain Worldwide: WHO 2Health News:Swine Flu Virus Dominant Strain Worldwide: WHO 3Health News:Local Medicare Advantage Plan Gets Five-Star Ratings from Medicare 2Health News:Local Medicare Advantage Plan Gets Five-Star Ratings from Medicare 3Health News:The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit; State Investigation Finds Evidence of Negligence at Woodbridge Day School 2Health News:ChemSW Rated Top Vendor Overall for Customer Satisfaction in Q3 2009 by VendorRate 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: